- Brings substantial pharmaceutical expertise to lead the development and commercialization of olorofim in the USA
- Ian Nicholson stepping down to pursue non-executive roles
MANCHESTER, UK / VIENNA, AUSTRIA, April 12, 2021 — F2G Limited (“F2G”), a clinical-stage biopharmaceutical company focused on life threatening fungal diseases, announces that Francesco Maria Lavino has been appointed Chief Executive Officer (CEO) and member of the Board of F2G. Mr. Lavino brings substantial specialty pharmaceutical leadership and expertise in the antifungal arena, including most notably, serving as AVP, Global Brand Leader, Anti-infectives portfolio at Merck & Co. and as Chief Commercial Officer of Nabriva Therapeutics, Inc. (NASDAQ: NBRV). Ian Nicholson is stepping down as CEO following eight years of dedicated service to F2G to pursue non-executive roles and will provide support to ensure an effective transition.